| Literature DB >> 26561522 |
Samira Bell1, Friedo W Dekker2, Thenmalar Vadiveloo3, Charis Marwick3, Harshal Deshmukh3, Peter T Donnan3, Merel Van Diepen2.
Abstract
STUDY QUESTION: What is the predicted risk of acute kidney injury after orthopaedic surgery and does it affect short term and long term survival?Entities:
Mesh:
Substances:
Year: 2015 PMID: 26561522 PMCID: PMC4641433 DOI: 10.1136/bmj.h5639
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Baseline characteristics of patients in the development and validation cohorts. Values are numbers (percentages) unless stated otherwise
| Characteristics | Development cohort (n=6220) | Validation cohort (n=4395) | |||||
|---|---|---|---|---|---|---|---|
| Acute kidney injury (n=672, 10.8%) | No acute kidney injury (n=5548) | Overall | Acute kidney injury (n=295, 6.7%) | No acute kidney injury (n=4100) | Overall | ||
| Mean (SD) age (years) | 76.5 (11.1) | 70.0 (15.6) | 70.7 (15.3) | 75.3 (10.2) | 70.7 (12.3) | 71.0 (12.3) | |
| Men | 314 (47) | 1980 (36) | 2294 (37) | 144 (49) | 1535 (37) | 1679 (38) | |
| Women | 358 (53) | 3568 (64) | 3926 (63) | 151 (51) | 2565 (63) | 2716 (62) | |
| Median (interquartile range) length of hospital stay (days) | 9 (5-15) | 8 (5-12) | 11 (5-12) | 7 (4-10) | 6 (5-8) | 6 (5-9) | |
| Baseline eGFR (mL/min) | 61 (25) | 72 (22) | 71 (23) | 65 (21) | 72 (19) | 72 (20) | |
| Chronic kidney disease category (eGFR mL/min): | |||||||
| >60 | 324 (48.2) | 3846 (69.3) | 4170 (67.0) | 180 (61.0) | 2963 (72.3) | 3143 (71.5) | |
| 45-59 | 155 (23.1) | 1077 (19.4) | 1232 (19.8) | 62 (21.0) | 788 (19.2) | 850 (19.3) | |
| 30-44 | 126 (18.8) | 491 (8.9) | 617 (9.9) | 39 (30.2) | 286 (7.0) | 325 (7.4) | |
| <29 | 67 (10.0) | 134 (2.4) | 201 (3.3) | 14 (4.7) | 63 (1.5) | 77 (1.7) | |
| SIMD deprivation category: | |||||||
| 1 (most deprived) | 144 (21.4) | 1026 (18.5) | 1170 (18.8) | 20 (6.8) | 279 (6.8) | 299 (6.8) | |
| 2 | 123 (18.3) | 932 (16.8) | 1055 (17.0) | 50 (16.9) | 471 (11.5) | 521 (11.9) | |
| 3 | 105 (15.6) | 992 (17.9) | 1097 (17.6) | 57 (19.3) | 761 (18.6) | 818 (18.6) | |
| 4 | 199 (29.6) | 1671 (30.1) | 1870 (30.1) | 100 (33.9) | 1613 (39.3) | 1713 (39.0) | |
| 5 (least deprived) | 89 (13.2) | 859 (15.5) | 948 (15.2) | 68 (23.1) | 919 (22.4) | 987 (22.5) | |
| Missing | 12 (1.8) | 12 (1.8) | 80 (1.3) | 0 | 57 (1.4) | 57 (13.0) | |
| No receiving NSAIDs | 101 (15) | 991 (17.9) | 1092 (17.6) | 56 (19.0) | 1112 (27.1) | 1168(26.6) | |
| No receiving ACE inhibitor or angiotensin II receptor antagonist | 322 (47.9) | 1371 (24.7) | 1693 (27.2) | 157 (53.2) | 1124 (27.4) | 1281 (29.1) | |
| No receiving statins | 293 (43.6) | 1595 (28.7) | 1888 (30.4) | 117 (39.7) | 1138 (27.8) | 1255 (28.6) | |
| No of prescribed drugs: | |||||||
| None | 136 (20.2) | 2090 (37.7) | 2226 (35.8) | 56 (19.0) | 1301 (31.7) | 1357 (30.9) | |
| 1 or 2 | 291 (43.3) | 2423 (43.7) | 2714 (43.6) | 133 (45.1) | 1950 (47.6) | 2083 (47.4) | |
| ≥3 | 245 (36.5) | 1035 (18.7) | 1280 (20.6) | 106 (35.9) | 849 (20.7) | 955 (21.7) | |
| Operation urgency: | |||||||
| Elective | 312 (46.4) | 2576 (46.4) | 2888 (46.4) | 212 (71.9) | 2973 (72.5) | 3185(72.5) | |
| Expedited | 174 (25.9) | 1410 (25.4) | 1584 (25.5) | 50 (16.9) | 588 (14.3) | 638 (14.5) | |
| Emergency | 186 (27.7) | 1562 (28.2) | 1748 (28.1) | 33 (11.2) | 539 (13.1) | 572 (13.0) | |
| Diabetes | 146 (21.7) | 524 (9.4) | 670 (10.8) | 50 (16.9) | 371 (9.0) | 421 (9.6) | |
| ASA grade: | |||||||
| 1 | 16 (2.4) | 675 (12.2) | 691 (11.1) | 19 (6.4) | 430 (10.5) | 449 (10.2) | |
| 2 | 212 (31.5) | 2070 (37.3) | 2282 (36.7) | 101 (34.2) | 1810 (44.1) | 1911 (43.5) | |
| 3 | 374 (40.8) | 1609 (29.0) | 1886 (30.3) | 89 (30.2) | 934 (22.8) | 1023 (23.3) | |
| 4 | 70 (10.4) | 368 (6.6) | 438 (7.0) | 31 (10.5) | 221 (5.4) | 252 (5.7) | |
| Missing | 100 (10.4) | 826 (14.9) | 926 (14.9) | 55 (18.6) | 705 (17.2) | 760 (17.3) | |
eGFR=estimated glomerular filtration rate; SIMD=Scottish index of multiple deprivation; NSAIDs=non-steroidal anti-inflammatory drugs; ACE=angiotensin converting enzyme; ASA=American Society of Anesthesiologists.
Predictive variables for acute kidney injury on multivariable logistic regression analysis of development cohort
| Predictors | β | Odds ratio (95% CI) | P value |
|---|---|---|---|
| Sex (female) | −0.708 | 0.493 (0.407 to 0.596) | <0.001 |
| Age at operation (years) | 0.022 | 1.022 (1.013 to 1.031) | <0.001 |
| Diabetes | 0.427 | 1.532 (1.199 to 1.959) | 0.001 |
| No of prescribed drugs: | |||
| None (reference) | — | — | 0.94 |
| 1 or 2 | 0.130 | 1.139 (0.889 to 1.463) | 0.308 |
| ≥3 | 0.347 | 1.415 (1.025 to 1.953) | 0.035 |
| ACE inhibitor or angiotensin receptor blocker | 0.534 | 1.705 (1.343 to 2.164) | <0.001 |
| Chronic kidney disease (eGFR mL/min): | |||
| >60 | −1.417 | 0.242 (0.168 to 0.351) | <0.001 |
| 45-59 | −1.108 | 0.330 (0.226 to.0483) | <0.001 |
| 30-44 | −0.676 | 0.508 (0.434 to 0.753) | 0.001 |
| <29 (reference) | — | — | <0.001 |
| ASA grade: | |||
| 1 | −1.037 | 0.355 (0.194 to 0.647) | 0.001 |
| 2 | −0.141 | 0.869 (0.633 to 1.192) | 0.384 |
| 3 | 0.014 | 1.014 (0.751 to 1.368) | 0.929 |
| 4 (reference) | — | — | 0.002 |
ACE=angiotensin converting enzyme; eGFR=estimated glomerular filtration rate; ASA=American Society of Anesthesiologists.
Intercept of model was −2.385.

Fig 1 Calibration in development and validation cohorts
Performance of prediction model in development and validation cohort
| Model performance | Apparent validation | Internal validation | External validation | ||||
|---|---|---|---|---|---|---|---|
| Development cohort | Development cohort (with bootstrapping) | Validation cohort | Validation cohort (recalibrated: method 1) | Validation cohort (recalibrated: method 2) | |||
| Calibration-in-the-large (%) | 10.8 | 10.8 | 10.4 | 6.8 | 6.6 | ||
| Calibration slope | 1.00* | 0.95 | 0.79 | 0.79 | 1.00* | ||
| Discrimination: C statistic | 0.74 | 0.73 | 0.70 | 0.70 | 0.70 | ||
*Perfect values by definition.

Fig 2 Calibration in validation cohort after recalibration using method 1 and method 2
Incidence of acute kidney injury across different risk categories in development and validation cohorts
| Predicted risk | Development cohort | Validation cohort | |||
|---|---|---|---|---|---|
| No of patients | Incidence of acute kidney injury (No) | No of patients | Incidence of acute kidney injury (No) | ||
| <0.05 | 1377 | 0.03 (36) | 972 | 0.03 (32) | |
| 0.05-0.10 | 1795 | 0.07 (123 | 1247 | 0.03 (36) | |
| 0.10-0.15 | 951 | 0.14 (129) | 658 | 0.10 (64) | |
| 0.15-0.20 | 481 | 0.19 (90) | 363 | 0.12 (42) | |
| 0.20-0.25 | 292 | 0.25 (72) | 170 | 0.17 (29) | |
| >0.25 | 398 | 0.31 (122) | 225 | 0.16 (37) | |

Fig 3 Kaplan Meier plot of overall survival in patients with acute kidney injury compared with no acute kidney injury
Comparison of short term and long term survival in patients with or without acute kidney injury
| Survival variables | No (%) of deaths | Hazard ratio (95% CI) | P value |
|---|---|---|---|
| Overall survival (crude) | 3166 (30) | 2.04 (1.84 to 2.26) | <0.001 |
| Overall survival (adjusted*) | 1.53 (1.38 to 1.70) | <0.001 | |
| 90 day (crude) | 604 (5.7) | 3.24 (2.68 to 3.91) | <0.001 |
| 90 day (adjusted) | 2.36 (1.94 to 2.87) | <0.001 | |
| 1 year (crude) | 543 (5.4) | 1.89 (1.49 to 2.41) | <0.001 |
| 1 year (adjusted) | 1.40 (1.10 to 1.79) | 0.007 | |
| Long term (crude) (end of follow-up) | 2019 (21.3) | 1.67 (1.45 to 1.94) | <0.001 |
| Long term (adjusted) (end of follow-up) | 1.23 (1.10 to 1.45) | 0.001 |
*Adjusted for age, sex, diabetes, baseline renal function, and number of prescribed drugs.
Overall adjusted survival according to severity of acute kidney injury
| Stage* | No of patients | No (%) of deaths | Hazard ratio (95% CI) | P value |
|---|---|---|---|---|
| 1 (mild) | 826 | 362 (22.8) | 1.46 (1.30 to 1.63) | <0.001 |
| 2 | 100 | 38 (38) | 2.08 (1.51 to 2.87) | <0.001 |
| 3 (severe) | 41 | 18 (43.9) | 2.77 (1.74 to 4.41) | <0.001 |
*According to Kidney Disease Improving Global Outcomes criteria.